Legacy Edge Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.06M Buy
5,715
+323
+6% +$69.5K 0.14% 81
2026
Q1
$1.17M Sell
5,392
-146
-3% -$32.4K 0.12% 89
2025
Q4
$1.27M Buy
+5,538
New +$1.26M 0.14% 85

Other funds holding ABBV

Legacy Edge Advisors's ABBV Position: Q2 2026 in Review

Legacy Edge Advisors increased its AbbVie (ABBV) stake by 6% in Q2 2026, buying an estimated $69.5K and bringing the position to 5,715 shares worth $1.06M. The position accounts for 0.14% of the portfolio, ranked #81.

Legacy Edge Advisors first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.27M in Q4 2025. 3,018 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Legacy Edge Advisors held 5,715 shares of AbbVie worth $1.06M as of Q2 2026.
  • Legacy Edge Advisors bought 323 AbbVie shares in Q2 2026, an estimated $69.5K.
  • AbbVie made up 0.14% of Legacy Edge Advisors's portfolio in Q2 2026, its #81 holding.
  • Legacy Edge Advisors first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
  • Legacy Edge Advisors's AbbVie position peaked at $1.27M in Q4 2025.
  • 3,018 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Legacy Edge Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.